论文部分内容阅读
乙型肝炎病毒(HBV)感染是造血干细胞移植患者面临的一个重要危险。移植后乙肝表面抗原携带者(HBsAg)尤其具有病毒再次激活的潜在风险〔1〕。在移植后也可以因为输入血制品导致乙肝急性感染。在免疫抑制治疗后因为导致肝细胞损伤的宿主细胞免疫反应被抑制,大多数感染乙肝的移植
Hepatitis B virus (HBV) infection is an important risk for patients with hematopoietic stem cell transplantation. Transplanted hepatitis B surface antigen carriers (HBsAg) in particular have the potential risk of reactivation of the virus 〔1〕. Acute infection of hepatitis B can also be caused by blood products after transplantation. After immunosuppressive therapy, the immune response of host cells is suppressed because of the hepatocyte damage. Most of the transplanted hepatitis B